Adipose tissue is specialised for lipid storage. When its expansion capacity is exceeded or its insulin response fails, excess lipid is deposited in organs not designed for sustained high-volume storage. This is called ectopic fat.
Ectopic fat is not one disease. Hepatic, intramuscular, pancreatic, epicardial and perivascular fat differ in biology, measurement and clinical significance. In some locations lipid intermediates contribute directly to dysfunction; in others visible fat is mainly a marker of broader energy surplus.
Triglyceride storage versus lipotoxicity
A triglyceride droplet may be a relatively inert buffer. Harm is more closely related to lipid flux and bioactive species—including selected diacylglycerols and ceramides—than to total triglyceride alone. Cellular location, turnover and oxidative capacity are therefore essential.
This distinction explains the athlete’s paradox: endurance-trained muscle may contain abundant intramyocellular triglyceride while remaining highly insulin sensitive.
Liver: the best-characterised ectopic depot
MASLD is defined by hepatic steatosis in association with cardiometabolic risk factors, after appropriate consideration of alcohol and other causes. Liver fat is closely related to hepatic insulin resistance and increased VLDL production.
Steatosis may remain stable or regress. In a subset, hepatocyte injury and inflammation develop as MASH, and fibrosis becomes the strongest determinant of liver-related outcomes. Normal aminotransferases do not exclude clinically important disease.
Current European guidance supports case-finding in at-risk groups and a stepwise fibrosis pathway, usually beginning with FIB-4 and followed, when indicated, by elastography or another validated second-line test. MRI-PDFF quantifies liver fat accurately but is not a routine population-screening tool.
Skeletal muscle
Myosteatosis includes abnormal fat within and around muscle. It is associated with ageing, inactivity, insulin resistance, lower strength and adverse outcomes. However, imaging definitions vary and the clinical meaning depends on whether fat is intramyocellular, intermuscular or replacing muscle tissue.
The practical priority is not to identify every lipid droplet but to preserve muscle mass, strength, mobility and metabolic capacity.
Pancreas
Higher pancreatic fat is associated with visceral adiposity, MASLD, insulin resistance and type 2 diabetes. Yet imaging combines several compartments and cannot establish that visible pancreatic fat directly causes beta-cell failure.
Weight-loss studies show that reduced pancreatic fat can accompany recovery of insulin secretion and diabetes remission in responders. This supports a role in the metabolic phenotype but does not establish a universal diagnostic threshold or justify routine screening for a “fatty pancreas”.
Heart and vessels
Epicardial fat lies between myocardium and visceral pericardium. Physiologically it supplies fuel and provides local protection. When enlarged and dysfunctional, it is associated with coronary disease, atrial fibrillation and heart failure with preserved ejection fraction. Local paracrine effects are plausible because there is no fascial barrier between this depot, coronary arteries and myocardium.
Perivascular adipose tissue normally releases anticontractile mediators. With adipose dysfunction it can become pro-oxidant and inflammatory, reducing nitric-oxide bioavailability and promoting vascular stiffness. These depots are promising mechanistic and imaging markers, but routine measurement is not yet a standalone clinical test.
Can ectopic fat fall before major weight loss?
Yes. Liver fat can decline within days to weeks of a meaningful negative energy balance and often falls proportionally more than total body weight. Exercise can reduce liver and visceral fat and improve muscle metabolism even with modest scale change.
The sequence differs by organ. Hepatic fat and insulin sensitivity often improve early; fibrosis, vascular remodelling, muscle quality and functional impairment may require longer and may not fully reverse.
Evidence hierarchy
| Claim | Level | Interpretation |
| Liver and visceral fat strongly track cardiometabolic risk. | A | Consistent imaging, cohort and intervention evidence. |
| Fibrosis risk, not steatosis alone, drives liver prognosis in MASLD. | A | Guidelines and longitudinal evidence converge. |
| Pancreatic fat directly causes type 2 diabetes in all patients. | C | Association is strong; causal contribution varies and thresholds are unvalidated. |
| Epicardial fat measurement should be used for universal screening. | D | Insufficient evidence for routine standalone use. |
Pathological Adiposity series
1. Pathological adiposity → 2. Metabolic inflammation → 3. Insulin resistance → 4. Ectopic fat → 5. Endothelial dysfunction and hypertension → 6. Reversibility.
Selected references
- Shulman GI. Ectopic fat in insulin resistance, dyslipidaemia and cardiometabolic disease. New England Journal of Medicine. 2014. DOI
- Neeland IJ, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease. Lancet Diabetes & Endocrinology. 2019. DOI30084-1)
- EASL–EASD–EASO. Clinical Practice Guidelines on MASLD. 2024.
Leave a Reply